Breast cancers are highly heterogeneous due to variations in the expression of hormone receptors (estrogen and progesterone receptors) and HER2, which necessitates different treatment approaches, such as hormonal therapy, HER2 targeted therapy, or chemotherapy, based on molecular subtypes. This evidence concerns the gene NR4A1 and breast carcinoma.